Nakamura T, Takebe K, Kudoh K, Ishii M, Imamura K, Kikuchi H, Kasai F, Tandoh Y, Yamada N, Arai Y
Third Department of Internal Medicine, Hirosaki University School of Medicine, Aomori, Japan.
Int J Pancreatol. 1995 Feb;17(1):29-35. doi: 10.1007/BF02788356.
The study was conducted on five healthy subjects and six patients with calcifying pancreatitis (CP) and steatorrhea. Following overnight fasting, one tube each was placed in the stomach and the upper of the small intestine, respectively. Through the gastric tube, a test meal that included 30 g of fat (total calories, 625 kcal, 500 mL) was infused over a span of 30 min. Every 30 min (up to 150 min), fluid samples in the upper small intestine were collected and chilled, and the amylase, trypsin, and lipase levels were determined. In addition, in the case of the CP patients, a high-potency pancreatin preparation was infused into the stomach together with the test meal. In order to determine the plasma CCK level, blood sample were collected before test meal infusion and at 10, 20, 30, 45, 60, 90, 120, and 150 min subsequent to infusion. The plasma CCK was extracted using a Sep-Pak C-18 cartridge and analyzed with radioimmunoassay using an OAL-656 antibody. The result was converted to the CCK-8 level and expressed in pg/mL. The enzyme activities in the upper small intestine of the CP patients after test meal administration amounted to 22.8 (amylase), 10.8 (trypsin), and 16.9% (lipase) compared with the corresponding figures for the normal subjects. Following administration of a high-potency pancreatin in patients with CP, enzyme activities in the upper small intestine increased to 132.2 (amylase), 38.7 (trypsin), and 45.3% (lipase) compared with levels in the normal subjects. However, the healthy subjects and the CP patients, both with and without treatment with supplementary exogenous enzymes, all exhibited similar profiles in the plasma CCK response to stimuli. Based on these findings, we concluded that a negative feedback mechanism does not exist between the tryptic activity of the upper small intestine and the CCK secretory response in patients with chronic pancreatitis.
该研究针对5名健康受试者以及6名患有钙化性胰腺炎(CP)并伴有脂肪泻的患者开展。在禁食过夜后,分别在胃和小肠上段各放置一根导管。通过胃管,在30分钟内输注一顿包含30克脂肪(总热量625千卡,500毫升)的试验餐。每隔30分钟(直至150分钟),收集小肠上段的液体样本并冷藏,然后测定淀粉酶、胰蛋白酶和脂肪酶水平。此外,对于CP患者,将一种高效胰酶制剂与试验餐一同注入胃中。为了测定血浆CCK水平,在试验餐输注前以及输注后10、20、30、45、60、90、120和150分钟采集血样。使用Sep-Pak C-18柱提取血浆CCK,并使用OAL-656抗体通过放射免疫分析法进行分析。结果转换为CCK-8水平,并以pg/mL表示。与正常受试者的相应数据相比,试验餐给药后CP患者小肠上段的酶活性分别为淀粉酶22.8、胰蛋白酶10.8以及脂肪酶16.9%。在CP患者中给予高效胰酶后,与正常受试者的水平相比,小肠上段的酶活性分别升至淀粉酶132.2、胰蛋白酶38.7以及脂肪酶45.3%。然而,无论是否接受补充外源性酶的治疗,健康受试者和CP患者在血浆CCK对刺激的反应方面均呈现出相似的特征。基于这些发现,我们得出结论,慢性胰腺炎患者小肠上段的胰蛋白酶活性与CCK分泌反应之间不存在负反馈机制。